

Klinische Studien

Stand 10.09.2018

NSCLC

Eudra-CT	Titel	Prüfsubstanz	Phase	Studienstand
2014-000323-25	A Randomized Open-Label Phase III Trial of Pembrolizumab versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer	Pembrolizumab	III	aktiv, keine Rekrutierung
2014-003207-30	A Phase III, open-label, randomized Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination with or without Bevacizumab compared with Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-naive Patients with Stage IV Non-squamous non-small Cell Lung Cancer.	MPDL3280A ± Bevacizumab	III	aktiv, keine Rekrutierung
2014-001983-36	Maintaining ERBB blockade in EGFR-mutated lung cancer (MARBLE) - A randomized, open-label, phase II study of maintaining pan-ERBB blockade following platinum-based induction chemotherapy in patients with EGFR mutated, metastatic non-small-cell lung cancer progressing after first line treatment with afatinib	Afatinib vs. Pemetrexed	II	aktiv, keine Rekrutierung
2014-003205-15	A Phase III, open-label, randomized study to investigate the efficacy and safety of Atezolizumab (Anti-PD-L1 Antibody) compared with best supportive care following adjuvant cisplatin-based Chemotherapy on PD-L1 selected Patients with completely resected Stage IB-IIIa Non-Small Cell Lung Cancer	Atezolizumab	III	aktiv
2015-001279-39	A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (MYSTIC)	MEDI4736	III	Nachbeobachtung
n.v.	Vagatref in der Zweitlinientherapie beim fortgeschrittenen oder metastasierten Adenokarzinom der Lunge	nicht interventionelle Studie		aktiv, keine Rekrutierung
2014-003804-66	A Phase III, randomized, open-label, multicenter, safety and efficacy Study to evaluate NAB-Paclitaxel (ABRAXANE®) as maintenance treatment after induction with NAB-Paclitaxel plus carboplatin in subjects with squamous cell non-small Cell Lung cancer (NSCLC)	NAB -Paclitaxel	III	Nachbeobachtung
n.v.	GIOTRIF® in der Erstlinientherapie des fortgeschrittenen NSCLC mit aktivierenden EGFR-Mutationen	nicht interventionelle Studie		aktiv, keine Rekrutierung
2015-000575-27	A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)	Pembrolizumab	III	aktiv
2014-003208-59	A Phase III, open-label, multicenter, randomized Study evaluating the efficacy and safety of MPDL3280A (Anti-PD-L1 Antibody) in combination with Carboplatin + Paclitaxel oder MPDL3280A in Combination with Carboplatin + NAB-Paclitaxel versus Carboplatin + NAB-Paclitaxel in Chemotherapy naïve Patients with Stage IV squamous Non-Small Cell Lung Cancer	MPDL3280A	III	Nachbeobachtung
2015-003694-15	A randomized, double-blind, Phase III Study of Platinum + Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in first Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (Keynote_189)	Pembrolizumab	III	aktiv, keine Rekrutierung
2015-004026-34	A Phase III, Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB8 (proposed bevacizumab biosimilar) and Avastin® in Subjects with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer	SB8 and Avastin	III	aktiv, keine Rekrutierung
2014-004095-31	A prospective phase II, randomized multi-center trial of a biomodulatory treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with squamous cell lung cancer or non-squamous cell lung cancer, respectively after platin failure	Nivolumab	II	aktiv
2014-003850-15	A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease	INC280	II	aktiv
2015-005741-31	Fostering efficacy of anti-PD1 - treatment in advanced and progressive NSCLC	anti-PD1-treatment	II	aktiv
2015-005696-24	a Phase II single-arm trial to investigate tepotinib in Stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing Regimen	Tepotinib	II	aktiv

2016-003315-35	A Phase 3, randomized, open-Label study of Lorlatinib (PF-06463922) Monotherapy versus Crizotinib Monotherapy in the first-line Treatment of Patients with advanced ALK-positive non-small Cell lung cancer.	Lorlatinib	III	onhold, neue Initiierung im Sept. 2018 geplant
in Planung	The Effectiveness of Atelzolizumab under real-world conditions in patientes with locally-advanced or metastatic Non small cell lung cancer after prior chemotherapy	nicht interventionelle Studie		in Planung

Pleuramesotheliom

Eudra-CT	Titel	Prüfsubstanz	Phase	Studienstand
2012-005201-48	Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed /cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma	Nintedanib	II/III	aktiv, keine Rekrutierung
2016-001859-43	A Phase III, randomized, open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or carboplatin as first line therapy in unresectable Pleural Mesothelioma.	Nivolumab + Ipilimumab	III	Nachbeobachtung